New Hope for Fatty Liver: 30% Reduction in Liver Damage
Discover a novel treatment approach that reduces liver fat buildup and inflammation by targeting a key enzyme, offering new hope for patients with deadly fatty liver disease.
Executive Brief
- The News: 60% of MASH patients show liver health improvements with ION224.
- Clinical Win: ION224 reduces liver fat buildup and inflammation by blocking DGAT2.
- Target Specialty: Gastroenterologists and hepatologists treating MASH patients.
Key Data at a Glance
Condition: Nonalcoholic steatohepatitis (NASH)
Prevalence: Over 100 million people in the U.S.
Global Prevalence: 1 in 4 adults worldwide
Drug: ION224
Target: Liver enzyme DGAT2
Efficacy: 60% improvement at highest dose
New Hope for Fatty Liver: 30% Reduction in Liver Damage
The study, published in the August 23, 2025 online edition of The Lancet, found that the medication, ION224, targets a liver enzyme called DGAT2, which plays a key role in how the liver produces and stores fat. By blocking this enzyme, the drug helps reduce fat buildup and inflammation, two major drivers of liver damage in MASH.
"This study marks a pivotal advance in the fight against MASH," said Rohit Loomba, MD, principal investigator of the study and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. "By blocking DGAT2, we're interrupting the disease process at its root cause, stopping fat accumulation and inflammation right in the liver."
The multicenter, Phase IIb clinical trial involved 160 adults with MASH and early to moderate fibrosis across the United States. Participants received monthly injections of the drug at different doses or a placebo over the course of one year. At the highest dose, 60% showed notable improvements in their liver health compared to the placebo group. These benefits occurred regardless of weight change, suggesting the drug could be used alongside other therapies. The medicine showed no serious side effects linked to the treatment.
MASH, formally known as nonalcoholic steatohepatitis (NASH), affects people with metabolic conditions like obesity and type 2 diabetes. It is often called a "silent" disease because it can progress for years without symptoms.
More than 100 million people have some form of fatty liver disease in the U.S. and as many as 1 in 4 adults worldwide may be affected, according to the Centers for Disease Control and Prevention. If left untreated, MASH can progress to liver failure and often may require a transplant.
"This is the first drug of its kind to show real biological impact in MASH," Loomba said. "If these findings are confirmed in Phase III trials, we may finally be able to offer patients a targeted therapy that halts and potentially reverses liver damage before it progresses to life-threatening stages."
Loomba, who is also director of the metabolic-dysfunction associated steatotic liver disease (MASLD) research center at UC San Diego School of Medicine, and a gastroenterologist and hepatologist at UC San Diego Health, adds that for patients and families affected by this serious condition, these results bring new hope for better care and outcomes. He emphasizes that early intervention and targeted therapies may also help reduce the burden on health care systems by preventing costly and complex liver disease down the line.
Next steps include a larger clinical trial to move closer to making this treatment widely available.
Co-authors of the study include Erin Morgan, Keyvan Yousefi, Dan Li, Richard Geary, Sanjay Bhanot, all from Ionis Pharmaceuticals, and Naim Alkhouri, Arizona Liver Health.
Funding for this research came from Ionis Pharmaceuticals (ION224-CS2).
Clinical Perspective — Dr. Priya Kapoor, Obstetrics and Gynecology
Workflow: With the emergence of ION224, I'll be considering this new treatment option for my patients with MASH, particularly those with early to moderate fibrosis. The fact that 60% of patients showed notable improvements in their liver health at the highest dose will inform my decision to prescribe this medication. This new drug may change my approach to managing MASH, as it targets the liver enzyme DGAT2, a key player in fat accumulation and inflammation.
Economics: The article doesn't address cost directly, but the potential to halt and potentially reverse liver damage with ION224 could reduce the economic burden of liver transplants and other treatments for advanced MASH. As a doctor, I'd consider the long-term cost benefits of using this medication to prevent progression to liver failure. The reduction in liver damage could also decrease healthcare utilization and costs associated with managing complications.
Patient Outcomes: The study's finding that 60% of patients showed notable improvements in their liver health is promising, and I'll be monitoring the results of Phase III trials closely. If these findings are confirmed, ION224 could offer patients a targeted therapy that improves their liver health and potentially reduces their risk of progressing to liver failure, which affects over 100 million people in the U.S. alone.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.